Overview

A Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab

Status:
Not yet recruiting

Trial end date:
2023-08-21

Target enrollment:

Participant gender:

Summary

Study ML43000 is a Phase IIIb/IV multicenter, open-label (visual assessor-masked) study designed to assess the efficacy and safety of PDS 100 mg/mL Q24W in patients with nAMD who have been previously treated with anti-VEGF agents other than ranibizumab. Approximately 200 patients will be enrolled at approximately 40 sites.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ranibizumab